RxDoctor Payments Data

Landon Brown, MD

Hematology · Charlotte, NCNPI 1528453388

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,333 of the $13,746 with a category attached, or 97.0%. 10 manufacturers reported payments, led by Pfizer at 40.7% of the total. That places this record below the midpoint for hematology clinicians in NC, where the typical reported total is $12,876.

$13,746in general payments, 2019–2025

Across 15 payments — averaging $916.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Merck$2K
  • Johnson & Johnson$2K
  • GSK$1K
  • Seagen Inc.$1K
  • Janssen Scientific Affairs, LLC$1K
  • plus $214 from 4 others
$316,139in research payments, 2019–2025

Across 7 payments — averaging $45,163 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$301K
  • Sumitomo Pharma America, Inc.$15K

What the payments were for

  • Consulting fees$13,33397%
  • Food & beverage$2622%
  • Education$1511%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,746 in reported general payments places this provider in the 50th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina

Medicare billing

Part B allowed, 2024
$71,628
Medicare patients
129
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate40$935,843
NubeqaDarolutamide53$701,358
InlytaAxitinib29$607,086
Abiraterone Acetate251$258,458
OrgovyxRelugolix88$237,717
XtandiEnzalutamide16$198,618
EliquisApixaban17$24,737
MyrbetriqMirabegron12$3,107
Prednisone124$651
Potassium Chloride22$476
Tamsulosin Hcl39$436
Ondansetron Hcl37$267
Dexamethasone18$221
Gabapentin11$192
Losartan Potassium15$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$5,600$631,82346 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,280$258,458251 claims
Astellas Pharma US IncXtandi, Myrbetriq$34$201,72528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 65 hematology providers in North Carolina.

Other hematology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →